Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Private label ranitidine

This article was originally published in The Tan Sheet

Executive Summary

The H2 antagonist has begun reaching shelves at drug chains and wholesalers, mass merchandisers, food chains and warehouse clubs nationwide, Toronto, Canada-based Novopharm says. The product began shipping July 19. Novopharm says its subsidiary, Granutec, has shipped over 170 mil. tablets "to meet anticipated consumer demand for the lower cost generic." Warner-Lambert lost marketing exclusivity for the reference drug, Zantac 75, June 19. FDA granted Novopharm 180 days of marketing exclusivity for the private label version that is set to expire Jan. 19; the decision was challenged by Apotex but upheld by a D.C. federal court June 15 (1"The Tan Sheet" June 21, p. 3)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS090142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel